Duramycin is a heavily post-translationally modified peptide that binds phosphatidylethanolamine. It has been investigated as an antibiotic, inhibitor of viral entry, therapeutic for cystic fibrosis, and tumor and vasculature imaging agent. Duramycin contains a β-hydroxylated Asp (Hya) and four macrocycles, including an essential lysinoalanine (Lal) crosslink. The mechanism of Lal formation is not known. We here show that Lal is installed stereospecifically by DurN via addition of Lys19 to a dehydroalanine. The structure of DurN reveals an unusual dimer with a new fold. Surprisingly, in the structure of duramycin bound to DurN, no residues of the enzyme are near the Lal. Instead, Hya15 of the substrate makes interactions with Lal suggesting it acts as a base to deprotonate Lys19 during catalysis. Biochemical data suggest that DurN preorganizes the reactive conformation of the substrate, such that the Hya15 of the substrate can serve as the catalytic base for Lal formation. Duramycin and closely related compounds are ribosomally synthesized and post-translationally modified peptides (RiPPs) produced by various actinomycetes 1-5 and marine symbionts 6 . Duramycin binds phosphatidylethanolamine (PE), a major structural phospholipid in mammalian and microbial cell membranes 7, 8 . Duramycin contains 19 amino acids, and five final posttranslational modifications (PTMs), including one lanthionine (Lan), two methyllanthionines (MeLan), an erythro-3-hydroxy-L-aspartic acid (Hya) resulting from the hydroxylation of Asp15, and one (2S,9S)-Lal (Figure 1). The carboxylate and hydroxyl groups of Hya15 make key interactions with the ethanolamine head group of PE, providing
nanomolar affinity and high specificity 9 . As such, duramycin has been investigated as an antibiotic 1-3 , inhibitor of viral entry 10 , therapeutic for cystic fibrosis 11 , and tumor and vasculature imaging agent 12, 13 .
Recently, divamide A, a close homolog of duramycin discovered from the symbiotic microbiome of small marine animals, was reported to display potent anti-HIV activity 6 .
Previous studies have identified the biosynthetic genes (dur) that introduce the PTMs 14 . The precursor peptide DurA is synthesized with an N-terminal leader peptide (LP), which is removed after maturation of a C-terminal core peptide (CP) (Fig. 1a ). Serine and threonine residues in the CP region of DurA are dehydrated by DurM to form dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues.
Subsequently, DurM catalyzes addition of cysteine thiols onto the β-carbon of Dha or Dhb to produce Lan or MeLan, respectively (Fig. 1a ). The final two PTMs are hydroxylation of Asp15 by DurX to generate Hya15 and formation of (2S,9S)-Lal, putatively by DurN-catalyzed addition of Lys19 to Dha6 ( Fig. 1a ) 14 . A previous study demonstrated that duramycin lacking Lal does not have antimicrobial activity 14 , indicating that the Lal linkage is critical to set up the PE binding pocket. DurN and its orthologs have no sequence homology with any characterized proteins, its mechanism of Lal formation is not known, and previous attempts to reconstitute its activity in vitro were unsuccessful 15 .
In this study, we demonstrate DurN activity in vitro and present the co-crystal structures of the protein with a substrate analog and product. We compared Lal formation under enzymatic and nonenzymatic conditions, indicating that only DurN catalyzes stereospecific and diastereoselective Lal formation. Our data suggest that DurN promotes Lal formation via an unusual substrate-assisted mechanism. DurN in vitro (blue). Formation of the Lal is monitored by reaction with DTT, which provides an adduct (3) if Lal is not generated (yellow). The y1 fragment ion is marked with an orange line; c, Compound 1 was reacted with MBP-DurN (top) or MBP (bottom), treated with DTT, and analyzed by LC-MS ( Supplementary Fig. 2 ). Expected and observed masses are listed in Supplementary Table 2 . d, LC-MS/MS analysis of the products in panel c.
RESULTS

In vitro DurN activity
DurN was expressed in Escherichia coli as an N-terminal fusion with maltose binding protein (MBP-DurN; Supplementary Fig. 1 ). To prepare its putative substrate, the precursor peptide DurA was converted in E. coli to an intermediate containing Lan, MeLan, and Hya residues, but lacking Lal 14 . After purification, the majority of the leader peptide was removed proteolytically by endoproteinase Glu-C, yielding compound 1 with three N-terminal residues (AlaPheAla) originating from the leader peptide ( Fig.   1a ,b). Before testing the activity of DurN with this putative substrate peptide, we first generated the desired product by coexpression of DurA with DurM, DurX, and DurN in E. coli, followed by Glu-C treatment resulting in compound 2 containing all the PTMs found in duramycin ( Fig. 1b) 14 . Because addition of Lys19 to Dha6 in peptide 1 to form the desired Lal does not lead to a change in mass nor a change in retention time, we adopted an indirect assay to follow Lal formation. Substrate 1 contains an electrophilic Dha, whereas product 2 does not. Hence, dithiothreitol (DTT) was used to monitor unreacted 1 by liquid chromatography-mass spectrometry (LC-MS) ( Supplementary Fig. 2 ). After reacting 1 with MBP-DurN in vitro followed by DTT treatment, the DTT adduct 3 was not observed, whereas compound 3 was formed nearly quantitatively in control assays (Fig. 1c ). The products were also analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), demonstrating that the y1 ion is observed for 1 and 3, but not for the product of the MBP-DurN reaction because of the formation of the Lal ring ( Fig.   1d ; Supplementary Fig. 2b ). Finally, as discussed in more detail in a later section, we hydrolyzed the product peptide of the MBP-DurN reaction and observed the presence of Lal by gas chromatography coupled to mass spectrometry (GC-MS). Thus, MBP-DurN catalyzes in vitro Lal formation in peptide 1 to form product 2.
The structure of DurN with a substrate analog
We removed the MBP tag from MBP-DurN (see Methods) and obtained crystal structures of DurN in complex with a substrate analog and in complex with duramycin. We generated an unreactive variant of 1 in which Dha6 (originating from Ser6 in DurA) was mutated to Ala (1-Dha6Ala, Supplementary Fig.   3a ). The structure of DurN with 1-Dha6Ala was solved to 1.90 Å resolution by single wavelength anomalous dispersion (SAD) methods using an iodide-soaked crystal. DurN also crystallized in the apo form and the structure was solved to 2.15 Å by molecular replacement using the SAD-derived coordinates ( Fig. 2a ). The overall structure of DurN consists of an interlaced homodimer where α-helix 1 of each monomer is engaged with residues from α-helices 2-6 in the adjacent monomer. The α-helices are followed by a single β-strand that forms an intermolecular, antiparallel interaction with its neighboring βstrand ( Fig. 2a,b) . A query against the PDB 16 using the DALI server 17 shows that DurN does not confidently resemble any known domain, indicating DurN contains a new protein fold and dimerization mode.
The homodimer contains two structural ions that are related by the pseudo two-fold symmetry axis of the DurN homodimer. Our data are consistent with potassium as the bound metal ions . DurN coordinates potassium at both sites via an octahedral array of oxygen ligands derived from amides in the backbone ( Supplementary Fig. 4 ). In addition to potassium, we also considered the possibility of magnesium ions bound at the ion binding sites and carried out equivalent rounds of refinement in REFMAC5 18 after modeling either potassium or magnesium ions independently. Whereas no positive signal was observed in the difference Fourier map (Fo -Fc) at 3σ for the corresponding potassium bound model, a positive difference signal was observed for the magnesium bound model ( Supplementary Fig. 4c ). Additional support for structural potassium ions was gathered by performing differential scanning fluorimetry (DSF), whereby DurN melting curves were obtained in the presence of various potassium or magnesium ion concentrations. While potassium ions conferred an increase in thermal stability of DurN as a function of ion concentration, magnesium ions had no effect on DurN thermal stability ( Supplementary Fig. 4a ,b). Molecular dynamics (MD) simulations also favor a structural potassium ion over magnesium ( Supplementary Fig. 5 ).
Analysis of simulated annealing difference Fourier maps (Fo -Fc) of the apo-structure and the structure with the bound substrate analog revealed electron density for 1-Dha6Ala from Gln3 to Gly16 
The structure of DurN with duramycin
The observed binding pose of 1-Dha6Ala does not provide an obvious mechanism of catalysis.
We therefore determined the 1.66 Å resolution structure of DurN bound to duramycin. This structure revealed additional electron density in both binding sites of the DurN dimer, enabling modeling of the entire duramycin, including the Lal linkage ( Fig. 2d,e ). Globally, the two ligand-bound structures are highly similar with an RMSD of 0.45 Å over 1400 atoms (including ligands) ( Fig. 2f ). The duramycinbound structure reaffirms that DurN does not provide any residues that could catalyze the Michael-type addition and suggests that DurN may mediate Lal formation by serving as a molecular scaffold to bring Dha6 and Lys19 in close proximity. Notably, a bidentate hydrogen-bond is observed between the guanidine of Arg17, the Hya15 hydroxyl group, and an amide backbone oxygen of Cys14 of duramycin ( Fig. 2g ). The Gln20 and Gln89 side chains of DurN further extend the hydrogen-bond network, and an electrostatic interaction is also observed between the carboxylate of Hya15 and Lys66 (Fig. 2g ). These interactions position one of the carboxylate oxygens of Hya15 at 3.3 Å from the Lal secondary amine nitrogen. Thus, it appears that DurN holds the Hya15 carboxylate of the substrate in a conformation that is poised to activate Lys19 (Scheme 1). The other Hya15 carboxylate oxygen is 4.1 Å from the α-carbon of Ala6. This suggests that it would shield the Si face of the reactive Dha6, thus promoting protonation by solvent of the enolate formed upon the addition of Lys19 from the more accessible Re face, resulting in the correct (2S,9S)-Lal diastereomer (Scheme 1). The structures do not provide any evidence for activation of the carbonyl oxygen of Dha6. In fact, the Ψ angle in Ala6 in duramycin is close to zero, very likely due to electrostatic repulsion between the carboxylate of Hya15 and the amide carbonyl of Ala6, which is directed towards the solvent. This strongly suggests that the reacting Dha6 is fixed in an s-cis conformation prior to cyclization, which has been found to be the more reactive form in other Michaeltype additions occurring in lanthipeptide biosynthesis 19 . 
Substrate-assisted Lal formation
The conformation of duramycin in the co-crystal structure is more constrained than the solution structure of its close analog cinnamycin bound to lysophosphatidylethanolamine (PDB 2DDE). Indeed, molecular dynamics simulations demonstrate that the conformation of duramycin relaxes upon removal of DurN ( Supplementary Fig. 6 ). Notably, in the absence of DurN, Hya15 moves away from the Si face of Dha6. Given the apparent importance of the hydroxy group of Hya15 for positioning its carboxylate, we also performed MD calculations on the complex in which this functionality was removed (i.e. Hya15 replaced by Asp). In the absence of the -hydroxy group, the carboxylate reorients to interact with Arg17 and Lys66, and thus the MD simulations predict it would no longer be available to act as a base ( Fig. 3 ).
To probe their roles, MBP-DurN variants of conserved residues ( Supplementary Fig. 7 ) were constructed and their activities determined with substrate 1. Ala substitutions at positions involved in substrate binding (Arg17, Gln20, Gln89, and Lys66) resulted in inactive proteins, and the same outcome was observed for Arg18, Trp68, and Glu106 that are at the dimerization interface ( Supplementary Fig. 8 & 9). To investigate the effect on affinity upon mutation of substrate binding residues, fluorescently labeled duramycin (Dur-FL; Supplementary Fig. 3 ) was used for fluorescence polarization (FP) studies.
Dur-FL bound to MBP-DurN with a Kd of 417 ± 6 nM ( Supplementary Fig. 10a ). Unlabeled duramycin and substrate 1 were then used in competition FP experiments providing inhibition constants (Ki) of 2.72 ± 0.01 μM and 16.8 ± 0.5 μM, respectively ( Supplementary Fig. 10b ). MBP-tagged DurN variants R17A, Q20A, and Q89A did not bind Dur-FL, R17K bound very weakly, and K66A provided a Ki of 7.43 ± 0.08 μM ( Supplementary Fig. 10b ). Collectively, the mutational data suggest that the binding modes observed in the co-crystal structures are functionally important because variants of residues that engage the substrate in the crystal are compromised with regards to both catalysis and substrate binding. Duramycin backbone and sidechains are shown as dark and light blue lines, respectively. Lysinoalanine (Lal), Hya/Asp15, Arg17 and Lys66 are shown as red, blue, yellow and grey sticks, respectively. DurN is shown as grey (chain A) and brown (chain B) transparent cartoons. Nonpolar hydrogens have been omitted for clarity. a, The hydrogen bond network between Arg17, Lys66 (both located in the enzyme DurN), Hya15 and Ala6 (both located in the substrate) observed in the crystallographic structures is maintained throughout the whole trajectory, as reflected by the conserved χ dihedral angle of Hya15 (carboxylate side chain) of ca. +60º. b, However, simply removing the β-hydroxy group in the Hya15Asp mutant disrupts this hydrogen bond network and compromises the integrity of the active site; the carboxylate side chain undergoes a 120º conformational twist and engages in electrostatic interactions with Arg17 and Lys66, trapping the catalytic base in a non-catalytic conformation as revealed by its χ dihedral angle. This computational observation rationalizes the lack of catalytic activity of DurN regarding Lal formation in the Hya15Asp mutant of 1. Conformational ensembles for each complex show 5 superimposed representative snapshots derived from the trajectories and reveal a more rigid complex when native duramycin is bound to DurN (c), unlike the more flexible arrangement with the Hya15Asp mutant (d). 
We also tested variants of substrate 1. To maintain the hydroxyl group of Hya but not its carboxylate, 1-Hya15Ser ( Supplementary Fig. 3c ) was prepared in similar fashion as 1 except for using DurA-D15S as a precursor peptide. 1-Hya15Ser was a poor substrate for MBP-DurN ( Supplementary Fig.   11 ), even though competition FP experiments show that this variant peptide inhibits Dur-FL binding with a Ki of 10.2 ± 0.3 μM ( Supplementary Fig. 10b ). Another variant, 1-Hya15Asp, was prepared by removing DurX from the E. coli co-expression system ( Supplementary Fig. 3f ). This variant was not processed by MBP-DurN in vitro ( Supplementary Fig. 11 ), in agreement with the predictions of the MD simulations described above. These data suggest that both functional groups on the Hya15 side chain (i.e. β-hydroxyl and γ-carboxylate) must be present for substrate to be processed by DurN.
Stereochemistry of enzymatic and non-enzymatic Lal formation
The observation that 1-Hya15Asp was not a substrate for DurN in vitro was surprising because several studies have shown that deoxyduramycin/deoxycinnamycin can be obtained by co-expression of DurA/CinA with DurM/CinM and DurN/CinN 20, 21 . Thus, it appears that in bacteria, the absence of the hydroxy group on Asp15 is not preventing Lal formation. To further investigate this apparent contradiction, we obtained deoxyduramycin by co-expressing DurA with DurM and DurN in E. coli ( Supplementary Fig. 3g ). The product was treated with Glu-C to remove most of the leader peptide, and the three residues remaining from the leader peptide were removed using aminopeptidase. To probe whether duramycin and deoxyduramycin contained Lal, each peptide was hydrolyzed under acidic conditions to their constituent amino acids, which were derivatized as described previously (see Methods) 15 . GC-MS analysis indicated that authentic duramycin isolated from the producer organism contained predominantly the natural LL-Lal isomer (Fig. 4a) , with a small amount of epimer that is likely formed during acid hydrolysis 6, 15 . However, deoxyduramycin formed in E. coli contained about equal amounts of two diastereomers. Peptide 1 was then exposed to alkaline conditions that were previously used to form the Lal non-enzymatically but for which the stereochemistry was not determined 15 . After removal of the leader peptide, hydrolysis and analysis by GC-MS, two diastereomers of Lal were detected in roughly equal amounts, which was also observed when using a commercial mixture of (2R,9S)-Lal and (2S,9S)-Lal standards (Fig. 4a) . In contrast, product 2 obtained in vitro from DurN-catalyzed Lal formation again existed predominately of the (2S,9S)-Lal isomer. Collectively, these findings therefore suggest that Lal formation in E. coli when DurN is absent is non-stereoselective and may be nonenzymatic.
To explore the ramifications of the stereochemical information, we determined the antimicrobial activity of authentic duramycin, DurN-generated duramycin, and chemically generated duramycin by an agar diffusion assay against Bacillus subtilis ATCC 6633. These compounds would all contain the Hya15 and would only differ in the Lal. As expected based on the stereochemical analysis (Fig. 4a) , the product of DurN catalysis showed a similar zone of growth inhibition as authentic duramycin, whereas nonenzymatically produced 2 showed a zone of inhibition roughly half the size (Fig. 4b ). coli (bottom trace). b, Agar diffusion growth inhibition assay for duramycin generated by DurN in vitro (I), chemically generated 2 (II), and duramycin from the native producer (III). Concentrations are in μM, and the indicator strain is Bacillus subtilis ATCC 6633. Ctrl, negative control containing buffer and the proteases used to remove the leader peptide.
Conclusion
In this study, we provide the first in vitro demonstration that DurN catalyzes Lal formation, a step that had been recalcitrant in previous studies 6, 15 . By comparing enzymatic and non-enzymatic Lal generation, our data suggest that DurN greatly facilitates the reaction and controls the stereoselectivity. Furthermore, our data shows that the enzyme does not require the leader peptide for catalysis. DurN has a unique fold and dimeric architecture, and in the co-crystal structures, the Lal is entirely solvent exposed and the Hya15 of the substrate is positioned to potentially act as a base during catalysis to deprotonate Lys19 to initiate the Michael addition. Additionally, Hya15 appears to shield the Si face of the enolate intermediate, such that protonation will only occur from the Re face, resulting in the correct (2S,9S)-Lal product. Mutational studies show that substrates that lack either the hydroxyl or carboxylate groups of Hya15 are not processed by DurN, despite maintaining binding affinity, suggesting both of these groups on the substrate are indispensable for catalysis. Merging the biochemical findings with structural and computational insights points to a mechanism whereby the substrate employs its own Hya15 as a catalytic base to facilitate a Michael addition and stereospecific enolate protonation, resulting in Lal formation between Lys19 and Dha6.
Author Contributions
L.
A. performed all biochemical assays, designed and analysed by L.A. and W.A.V., and D.P.C. and S.K.N. performed and interpreted all structural studies. C.D.N. and G.O. performed the computational analysis. L.A., D.P.C., S.K.N. and W.A.V. wrote the manuscript. L.A. and D.P.C. contributed equally to this study.
Author Information
Atomic coordinates and structure factors for the reported crystal structure are deposited in the Protein 
Methods
General methods
Positive numbers are used for amino acids in the core peptide counting towards the C-terminus from the leader peptide cleavage site. Negative numbers are used counting backwards from the cleavage site.
Polymerase chain reactions (PCRs) were carried out on an automated thermocycler (C1000 TM , Bio-Rad).
Gibson Assembly reaction solutions were made as reported 22 The following procedures are the same for all preparations. A single colony was picked and grown in 5 mL of LB at 37 °C for 12 h containing antibiotics as described above, and the resulting culture was used to inoculate 1 L of LB containing the same antibiotics. When the OD600 reached 0.75, the cultures were cooled on ice for 30 min, and then IPTG was added to 1.0 mM. The cells were cultured at 18 °C for another 18 h before harvesting by centrifugation at 8,000 × g for 10 min. Cell pellets were resuspended at room temperature in LanA buffer 1 (6 M guanidine hydrochloride, 500 mM NaCl, 0.5 mM imidazole, 20 mM NaH2PO4, pH 7.5 at 25 °C) followed by sonication. The lysates were centrifuged at 18,000 ×g for 30 min and supernatants were passed through 0.45-µm syringe filters. His-tagged modified peptides were purified by immobilized metal affinity chromatography (IMAC) loaded with nickel as previously described 13 . The fractions with the desired peptide were desalted by preparative RP-HPLC using an Agilent Bond Elut C18 column (3 mL). The desalted peptides were lyophilized, dissolved in 50 mM Tris pH 7.5 buffer, and digested by endoproteinase GluC at 20:1 (w/w). The digested reaction mixtures were purified by reversed-phase prep-HPLC (see General Methods).
To prepare deoxyduramycin, the peptide was digested with aminopeptidase (0.1 U per µg of peptide) at pH 8.5 at room temperature overnight and purified by analytical HPLC (General Methods).
Dithiothreitol (DTT) assay to detect uncyclized Dha
DTT was dissolved in water at 1 M then aliquoted and stored at −20 °C for up to two weeks. DTT solutions were added to the peptide solutions to give a final concentration of 250 mM, and pH was adjusted (if necessary) to 7.5. Reactions were conducted at 37 °C for 30 min before.
Preparation of duramycin and 4 (non-enzymatic reaction) in vitro
Compound 1 was incubated with MBP-DurN (5:1, peptide : enzyme) in 100 mM Tris-HCl pH 7.5, 300 mM KCl, and 10 mM MgCl2 at 37 °C for 12 h. No DTT addition to the peptide indicated full conversion of 1. The reaction mixture was purified by analytical HPLC (see General Methods) and fractions containing 1 (judged by MS) were lyophilized. The dried peptide was dissolved in 50 mM Tris pH 8.5, then aminopeptidase was added at 0.1 U/μg of peptide, and the reaction mixture was incubated at 37 °C for 12 h to remove the residual leader peptide residues. The reaction mixture was analyzed by analytical HPLC (General Methods), MALDI-TOF-MS, LC-MS, and LC/MSMS indicating production of duramycin. For the preparation of 4, compound 1 was incubated in 50 mM Tris-HCl pH 10 at r.t. for 12 h and the DTT assay indicated full consumption of 1. Purification and removal of residual leader peptide residues to yield 4 was carried out as described above. Peptide concentrations were estimated by comparing the peak area at 214 nm in the LC chromatogram to that of authentic duramycin.
Activity assays for DurN and its mutants with 1 and its variants
All assays were performed with 50 μM modified DurA or its variants with 10 μM or 5 μM MBP-DurN or its mutants in 100 mM Tris-HCl pH 7.5, 300 mM KCl, and 50 mM MgCl2. A positive control with MBP-DurN and compound 1 and a negative control with just MBP and compound 1 were included as well as a negative control where MBP-DurN (or its mutants) was omitted; control reactions were conducted in parallel to the reaction of interest under the same conditions. Reactions were incubated at 37 °C for 1 h then treated with DTT using the procedure described above 
Crystallographic data collection, structure solutions, and refinement
Data were collected at the Advanced Photon Source at Argonne National Lab using the Life-Science Collaborative Access Team 21-ID-D, 21-ID-F, and 21-ID-G beamlines. Before collecting data, crystals were cryoprotected by immersing the crystals in similar solutions supplemented with 20% ethylene glycol and then flash-freezing in liquid nitrogen. To obtain phases experimentally, co-crystals of DurN and compound 1-Dha6Ala were soaked with 0.5 M potassium iodide for 24 h at 16 °C and used to collect diffraction data at 8 keV. Data were initially processed using autoPROC 23 and further processed in autoSHARP to obtain phase information. The initial model was rebuilt using Buccaneer 24 and refined using REFMAC5 25 in the CCP4 Software Suite. Diffraction datasets corresponding to apo DurN crystals and DurN-duramycin co-crystals were phased after similar processing in autoPROC followed by molecular replacement using Phaser MR 26 . Ligand parameters for compound 1-Dha6Ala and duramycin were determined using Phenix eLBOW 27 and modeled into their corresponding electron densities, followed by iterative rounds of automated REFMAC5 refinement and manual rebuilding in Coot 28 .
Solvent molecules and potassium ions were first incorporated using Phenix Refine 29 or REFMAC5 then manually curated in Coot.
Preparation and purification of compound Dur-FL
Duramycin (1 mg) was dissolved in 50 mM HEPES pH 7.5. Carboxyfluorescein succinimidyl ester (2 mg) was dissolved in 10 μL of dimethyl sulfoxide and added (total reaction volume = 1 mL). The reaction was left at r.t. in the dark for 2 h, desalted and analyzed by MS indicating both doubly and singly acylated duramycin. The products were purified by analytical HPLC (see General Methods), lyophilized, and stored at −20 °C. Peptide concentration was estimated by comparing the peak area at 214 nm to that of duramycin and NHS-Fluorescence standard. Where y is polarization, A1 is the minimum polarization, A2 is the maximum polarization, X0 is the IC50, p is the Hill coefficient, and x is the concentration of Dur-FL. 
Fluorescence polarization (FP) binding studies
Competition fluorescence polarization (FP) binding studies
2
Where yo is the initial bound to free ratio for the labeled species before perturbation of equilibrium by the added inhibitor, and LT is the total amount of labeled species.
Derivatization of lysinoalanine (Lal) standard
MeOD-d4 (3 mL) was cooled in a 50 mL pear-shaped glass flask immersed in an ice-water bath. Acetyl chloride (0.9 mL) was added dropwise. This solution was added to 2 mg Lal standard (LL and DLlysinoalanine mixture, Bachem) and the reaction mixture was heated at 110 °C for 1 h under reflux, then allowed to cool down to r.t. in air. The solvent was removed by a stream of nitrogen gas. Dichloromethane (3 mL) and pentafluoropropionic anhydride (1 mL) were added to the flask cooled in an ice-water bath.
The mixture was heated at 110 °C under reflux for 30 min, allowed to cool to r.t., and the solvent was removed under a stream of nitrogen gas for 2 h. For each sample, 800 μL of pyridine was used to dissolve all resulting compounds, and the solutions were directly analyzed by GC-MS.
Hydrolysis and derivatization of duramycin, compound 4, and deoxyduramycin
The same hydrolysis and derivatization procedures were applied for all Lal-containing samples. To 1 mg of peptide, 3 mL of 6 M deuterium chloride in D2O was added to the sample (~1 mg) in a glass pressure tube (Ace Glass). The reaction mixture was heated without stirring at 80 °C for 4 h. The solution was transferred to a 50 mL pear-shaped bottle, and the solvent was removed with a rotary evaporator. Then the same derivatizing procedures were used as described for the derivatization of Lal standard.
GC-MS analysis of lysinoalanine standard, duramycin, compound 4, and deoxyduramycin
The derivatized samples were analyzed by GC-MS using an Agilent 7890 gas chromatograph equipped with a ZB-1MS column (Phenomenex, 30 m x 0.25 mm x 0.25 μm). Samples were dissolved in 300 L of pyridine and a small volume introduced to the instrument via a splitless injection at a flow rate of 1.6 mL/min helium gas. The front inlet was set to 230 °C for initial temperature, the purge flow was 20 mL/min, the purge time was 1 min, and the total flow was 24 mL/min. The flow rate in the column was 1.6 mL/min. The temperature method used for the oven was 100 °C for 2 min, followed by 100 °C to 215 °C at 2.5 °C /min, and 215 °C for 2 min. The mass spectrometer was operated in simultaneous scan/selected-ion monitoring (SIM) mode, monitoring at the characteristic fragment masses of 190 Da, 
MD simulations
Unconstrained MD simulations in water were performed using the Amber 16 and AmberTools 17 package 32 . Parameters for dehydro amino acids, (methyl)lanthionine, Hya and Lal were generated using the general AMBER force field (gaff2) 32 , with partial charges set to fit the electrostatic potential generated at the HF/6-31G(d) level by the RESP (restrained electrostatic potential) model 33 . Water molecules were treated with the SHAKE algorithm. Long-range electrostatic effects were modelled using the particle mesh Ewald method 34 . An 8 Å cutoff was applied to Lennard-Jones and electrostatic interactions. The
Andersen equilibration scheme was used to control and equalize the temperature with a 2 fs time step at a constant volume and temperature of 300 K. Production trajectories were run for 1.0 μs.
